Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rolapitant Dose Finding in CINV
NCT00394966Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Sep 2006
- Primary completion
- Mar 2008
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, double-blind trial of rolapitant in chemotherapy-induced nausea and vomiting (CINV) (5 arms), sponsored by Merck & Co. Primary endpoint: Overall Complete Response Rate. Started Sep 2006; status: completed.
02
Drugs
rolapitant
03
Conditions
chemotherapy-induced nausea and vomiting (CINV)
Beyond the preview
Go deeper on NCT00394966.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00394966.